Name in SEC filings: Opus Genetics, Inc.
| Program | Event | Stage | Stated timing | Filing |
|---|---|---|---|---|
| OPGx-BEST1 | Other | Stage not stated | in 2026 | 8-K · |
| OPGx-LCA5 | Other | Phase 3 | in the fourth quarter of 2026 | 8-K · |
| OPGx-RDH12 | Other | Stage not stated | in the fourth quarter of 2026 | 8-K · |
| OPGx-MERTK | Other | Stage not stated | in the first quarter of 2027 | 8-K · |
| OPGx-BEST1 | /data readout | Stage not stated | in Q2 2027 | 8-K · |
| OPGx-BEST1 | Topline/data readout | Stage not stated | in Q2 2027 | 8-K · |
| OPGx-BEST1 | Other | Stage not stated | in 2027 | 8-K · |
| OPGx-RHO | Other | Stage not stated | in the second half of 2027 | 8-K · |
| OPGx-LCA5 | Topline/data readout | Stage not stated | by the end of 2027 | 8-K · |
Source: ORION, orionbiotechai.com/company/IRD, data as of Oct 16, 2026
https://www.orionbiotechai.com/company/IRD
OPGx-BEST1 · Other · in Q4 2026
SEC sources last checked .
○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.
Otherin Q4 2026
Stage: Not stated
Public float: Unknown (no public float found in SEC filings).
Based on the safety profile and positive proof-of-concept findings from Cohort 1, the Company has advanced to the higher-dose Cohort 2, evaluating OPGx-BEST1 at 4.5 x 10⁹ vg/eye, with dosing expected to be completed in Q4 2026 and topline three-month data expected in Q2 2027.
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
Otherin the fourth quarter of 2026
Stage: Phase 3SEC filing · “Phase 3”
Public float: Unknown (no public float found in SEC filings).
The Phase 3 clinical trial’s natural history and treatment cohorts are fully enrolled, with dosing initiation expected in the fourth quarter of 2026.
SEC timing context:
Based on the encouraging Phase 1/2 findings, Opus advanced OPGx-LCA5 into Phase 3 development using the low dose without requiring further dose escalation.
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
Otherin the fourth quarter of 2026
Stage: Not stated
Public float: Unknown (no public float found in SEC filings).
The OPGx-RDH12 program is expected to enter the clinic in the fourth quarter of 2026 and is partially funded through a partnership with the RDH12 Alliance.
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
Otherin the first quarter of 2027
Stage: Not stated
Public float: Unknown (no public float found in SEC filings).
The OPGx-MERTK program is expected to initiate clinical testing at the Cleveland Clinic Abu Dhabi in the first quarter of 2027.
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2027-03)
Topline/data readoutin Q2 2027
Stage: Not stated
Public float: Unknown (no public float found in SEC filings).
The Company expects to announce 6-month data for the three participants with BVMD in Q2 2027.
SEC timing context:
BIRD-1
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2027-06)
Topline/data readoutin Q2 2027
Stage: Not stated
Public float: Unknown (no public float found in SEC filings).
Based on the safety profile and positive proof-of-concept findings from Cohort 1, the Company has advanced to the higher-dose Cohort 2, evaluating OPGx-BEST1 at 4.5 x 10⁹ vg/eye, with dosing expected to be completed in Q4 2026 and topline three-month data expected in Q2 2027.
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2027-06)
Otherin 2027
Stage: Not stated
Public float: Unknown (no public float found in SEC filings).
The Company expects to begin planning for the Phase 3 trial immediately, with participant dosing expected to begin in 2027.
SEC timing context:
The Company also aligned with the FDA on Phase 3 and commercial manufacturing requirements, which it expects to complete in early 2027.
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2027-12)
Otherin the second half of 2027
Stage: Not stated
Public float: Unknown (no public float found in SEC filings).
The OPGx-RHO program is expected to initiate clinical testing globally in the second half of 2027.
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2027-12)
Topline/data readoutby the end of 2027
Stage: Not stated
Public float: Unknown (no public float found in SEC filings).
Topline data from the study is expected by the end of 2027.
SEC timing context:
Enrollment in the trial was completed, with dosing of OPGx-LCA5 expected to begin in the fourth quarter of 2026 using clinical drug supply manufactured with the intended commercial processes.
8-K · Filed · Last checked
Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .
| Program / event | Stated period and SEC wording | Disclosure in stated period |
|---|---|---|
| OPGx-LCA5Other | in the fourth quarter of 2026“The Phase 3 clinical trial’s natural history and treatment cohorts are fully enrolled, with dosing initiation expected in the fourth quarter of 2026.” Filed · EX-99.1 | Still within period As of Oct 19, 2026 |
| OPGx-BEST1Clinical results | in Q2 2027“The Company expects to announce 6-month data for the three participants with BVMD in Q2 2027.” Filed · EX-99.1 | Period not started The stated period has not started yet, so there is nothing to compare. |
| OPGx-BEST1Clinical results | in Q2 2027“Based on the safety profile and positive proof-of-concept findings from Cohort 1, the Company has advanced to the higher-dose Cohort 2, evaluating OPGx-BEST1 at 4.5 x 10⁹ vg/eye, with dosing expected to be completed in Q4 2026 and topline three-month data expected in Q2 2027.” Filed · EX-99.1 | Period not started The stated period has not started yet, so there is nothing to compare. |
| OPGx-BEST1Other | in Q4 2026“Based on the safety profile and positive proof-of-concept findings from Cohort 1, the Company has advanced to the higher-dose Cohort 2, evaluating OPGx-BEST1 at 4.5 x 10⁹ vg/eye, with dosing expected to be completed in Q4 2026 and topline three-month data expected in Q2 2027.” Filed · EX-99.1 | Still within period As of Oct 19, 2026 |
| OPGx-BEST1Other | in 2027“The Company expects to begin planning for the Phase 3 trial immediately, with participant dosing expected to begin in 2027.” Filed · EX-99.1 | Period not started The stated period has not started yet, so there is nothing to compare. |
| OPGx-LCA5Other | in the fourth quarter of 2026“Enrollment in the trial was completed, with dosing of OPGx-LCA5 expected to begin in the fourth quarter of 2026 using clinical drug supply manufactured with the intended commercial processes.” Filed · EX-99.1 | Still within period As of Oct 19, 2026 |
| OPGx-LCA5Clinical results | by the end of 2027“Topline data from the study is expected by the end of 2027.” Filed · EX-99.1 | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| OPGx-MERTKOther | in the first quarter of 2027“The OPGx-MERTK program is expected to initiate clinical testing at the Cleveland Clinic Abu Dhabi in the first quarter of 2027.” Filed · EX-99.1 | Period not started The stated period has not started yet, so there is nothing to compare. |
| OPGx-RDH12Other | in the fourth quarter of 2026“The OPGx-RDH12 program is expected to enter the clinic in the fourth quarter of 2026 and is partially funded through a partnership with the RDH12 Alliance.” Filed · EX-99.1 | Still within period As of Oct 19, 2026 |
| OPGx-RHOOther | in the second half of 2027“The OPGx-RHO program is expected to initiate clinical testing globally in the second half of 2027.” Filed · EX-99.1 | Period not started The stated period has not started yet, so there is nothing to compare. |
“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.
Suggest an SEC timing statement to add for IRD. You can include the original filing link in your note. The founder reads each request by hand.
Or email ORION.
See IRD in the calendar · Review labels and methodology